Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

Authors

Byram H Ozer, Scott M Lindhorst, Ryan T Merrell, Christopher R Trevino, Jeremy D Rudnick, Nicolas G Avgeropoulos, Naren Ramakrishna, Simon Khagi, Yasmeen Rauf, Tobias Walbert, Edward Pan, Michael Youssef, Karen L Fink, Jacob J Mandel, Lynne P Taylor, Howard Colman, Erin M Dunbar, Nina Paleologos, Eric C Burton, Jing Wu, Heather E Leeper, Javier Gonzalez, Marta Penas-Prado, Jeffrey J Raizer, Eleonora Veglia, Sandra Craig, Ying Yuan, Claudia Chambers, Kathleen Wall, Ewa Grajkowska, Tito Mendoza, Terri S Armstrong, Mark R Gilbert

Published in

medRxiv : the preprint server for health sciences. Jun 24, 2026. Epub Jun 24, 2026.

Abstract

GBM is one of the most common and most aggressive brain tumors in adults, and upfront standard of care treatment has limited efficacy. Immune checkpoint inhibitor strategies have significantly improved outcomes in various solid tumors but have not proven effective in GBM, suggesting other strategies may be needed to realize their full potential.
GBM patients were treated with upfront standard of care chemoradiation with temozolomide and pembrolizumab, followed by adjuvant temozolomide and pembrolizumab for six nine-week cycles. Depending on production of sufficient vaccine, patients were randomized into HSPPC-96 vaccine or placebo group (q4 weeks) while those with failed vaccine production continued on study unblinded as an ancillary group. The primary objective was overall survival at one year, and secondary endpoints were progression-free survival at six months, overall and progression-free survival, radiographic response, and tolerability by patient-reported outcomes and adverse event documentation.
90 patients were screened, 32 were treated (8 vaccine, 9 placebo, 15 ancillary), and 26 were evaluable for radiographic responses prior to accrual termination. The study did not meet its primary endpoint of overall survival at one year (65.5% in vaccine group, 75% in placebo). Progression-free endpoints were mildly improved in the vaccine group but were not significant, and response rates were not significantly different. The regimen was well-tolerated and safe.
Though limited by early discontinuation, these findings do not support the combination of pembrolizumab and HSPPC-96 vaccine with standard of care therapy.
ClinicalTrials.gov identifier: NCT03018288.
Newly diagnosed glioblastoma (GBM) has one standard of care treatment option with known limitations.Combination of standard of care therapy with immunotherapeutics consisting of pembrolizumab and the personalized cancer-derived HSPPC-96 vaccine is safe and well-tolerated in newly diagnosed GBMThis regimen demonstrated no survival benefit, but the vaccine safety profile recommends consideration of alternative combinatorial strategies.
In this phase 2, multicenter, placebo-controlled, double-blinded trial of newly diagnosed GBM patients, the addition of pembrolizumab and patient tumor-derived HSPPC-96 vaccine to standard of care chemoradiation and adjuvant temozolomide was not effective even accounting for early termination due to accrual issues during the Covid pandemic. However, with good safety profile and tolerability, HSPPC-96 vaccine could be considered in combination with other immunotherapeutic strategies in future GBM trials.

PMID:
42396282
Bibliographic data and abstract were imported from PubMed on 03 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.